{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:45:01Z","timestamp":1794048301128,"version":"4.8.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006400","name":"Alnylam Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006400","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.amjmed.2022.01.003","type":"journal-article","created":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T11:39:51Z","timestamp":1643024391000},"page":"S38-S43","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"special_numbering":"S1","title":["Renal Amyloidosis: Presentation, Diagnosis, and Management"],"prefix":"10.1016","volume":"135","author":[{"given":"Reena","family":"Gurung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.amjmed.2022.01.003_bib0001","first-page":"770","article-title":"Systemic amyloidosis: novel therapies and role of biomarkers","volume":"32","author":"Nuvolone","year":"2017","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1016\/j.amjmed.2022.01.003_bib0002","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1681\/ASN.2015111228","article-title":"Novel type of renal amyloidosis derived from apolipoprotein-CII","volume":"28","author":"Nasr","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"10.1016\/j.amjmed.2022.01.003_bib0003","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1097\/PAS.0b013e3181abdfa7","article-title":"Prevalence and origin of amyloid in kidney biopsies","volume":"33","author":"von Hutten","year":"2009","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1016\/j.amjmed.2022.01.003_bib0004","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.path.2014.04.006","article-title":"Renal amyloidosis","volume":"7","author":"Mohamed","year":"2014","journal-title":"Surgical pathology clinics."},{"issue":"9","key":"10.1016\/j.amjmed.2022.01.003_bib0005","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/ki.2010.9","article-title":"Prevalence and morphology of leukocyte chemotactic factor 2-associated amyloid in renal biopsies","volume":"77","author":"Larsen","year":"2010","journal-title":"Kidney Int"},{"issue":"12","key":"10.1016\/j.amjmed.2022.01.003_bib0006","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1681\/ASN.2006050460","article-title":"Amyloidosis-associated kidney disease","volume":"17","author":"Dember","year":"2006","journal-title":"J Am Soc Nephrol"},{"issue":"23","key":"10.1016\/j.amjmed.2022.01.003_bib0007","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1056\/NEJMoa070265","article-title":"Natural history and outcome in systemic AA amyloidosis","volume":"356","author":"Lachmann","year":"2007","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.amjmed.2022.01.003_bib0008","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.2215\/CJN.10491012","article-title":"Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases","volume":"8","author":"Said","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"10.1016\/j.amjmed.2022.01.003_bib0009","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.2215\/CJN.12551214","article-title":"Leukocyte cell-derived chemotaxin 2-associated amyloidosis: a recently recognized disease with distinct clinicopathologic characteristics","volume":"10","author":"Nasr","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"issue":"12","key":"10.1016\/j.amjmed.2022.01.003_bib0010","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.1681\/ASN.2005040382","article-title":"Renal apolipoprotein A-I amyloidosis: a rare and usually ignored cause of hereditary tubulointerstitial nephritis","volume":"16","author":"Gregorini","year":"2005","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.amjmed.2022.01.003_bib0011","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.kint.2016.04.003","article-title":"Clinical, biopsy, and mass spectrometry characteristics of renal apolipoprotein A-IV amyloidosis","volume":"90","author":"Dasari","year":"2016","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.amjmed.2022.01.003_bib0012","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0272-6386(96)90250-4","article-title":"Extracapillary glomerulonephritis and renal amyloidosis","volume":"28","author":"Moroni","year":"1996","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1016\/j.amjmed.2022.01.003_bib0013","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1159\/000186166","article-title":"Renal amyloidosis associated with antiglomerular basement membrane disease","volume":"56","author":"Gallo","year":"1990","journal-title":"Nephron"},{"issue":"10","key":"10.1016\/j.amjmed.2022.01.003_bib0014","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.disamonth.2014.08.003","article-title":"Renal amyloidosis","volume":"60","author":"Jazbeh","year":"2014","journal-title":"Dis Mon"},{"issue":"5","key":"10.1016\/j.amjmed.2022.01.003_bib0015","doi-asserted-by":"crossref","first-page":"851","DOI":"10.2214\/ajr.129.5.851","article-title":"Radiologic findings in renal amyloidosis","volume":"129","author":"Ekelund","year":"1977","journal-title":"AJR Am J Roentgenol"},{"issue":"6","key":"10.1016\/j.amjmed.2022.01.003_bib0016","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1002\/art.21902","article-title":"Diagnostic accuracy of subcutaneous abdominal fat tissue aspiration for detecting systemic amyloidosis and its utility in clinical practice","volume":"54","author":"van","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.amjmed.2022.01.003_bib0017","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1093\/ndt\/gfh503","article-title":"AL-amyloidosis is underdiagnosed in renal biopsies","volume":"19","author":"Novak","year":"2004","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1016\/j.amjmed.2022.01.003_bib0018","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.kint.2019.05.027","article-title":"The sensitivity and specificity of the routine kidney biopsy immunofluorescence panel are inferior to diagnosing renal immunoglobulin-derived amyloidosis by mass spectrometry","volume":"96","author":"Gonzalez Suarez","year":"2019","journal-title":"Kidney Int"},{"issue":"4","key":"10.1016\/j.amjmed.2022.01.003_bib0019","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ajh.20381","article-title":"Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004","volume":"79","author":"Gertz","year":"2005","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.amjmed.2022.01.003_bib0020","doi-asserted-by":"crossref","first-page":"988","DOI":"10.3324\/haematol.2012.079210","article-title":"A detailed evaluation of the current renal response criteria in AL amyloidosis: is it time for a revision?","volume":"98","author":"Leung","year":"2013","journal-title":"Haematologica"},{"issue":"15","key":"10.1016\/j.amjmed.2022.01.003_bib0021","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","article-title":"A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis","volume":"124","author":"Palladini","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.amjmed.2022.01.003_bib0022","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/joim.13169","article-title":"Systemic amyloidosis from A (AA) to T (ATTR): a review","volume":"289","author":"Muchtar","year":"2021","journal-title":"J Intern Med"},{"issue":"3","key":"10.1016\/j.amjmed.2022.01.003_bib0023","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2215\/CJN.06290615","article-title":"Trends in survival and renal recovery in patients with multiple myeloma or light-chain amyloidosis on chronic dialysis","volume":"11","author":"Decourt","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"10.1016\/j.amjmed.2022.01.003_bib0024","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/ajh.24738","article-title":"Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapy","volume":"92","author":"Kastritis","year":"2017","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.amjmed.2022.01.003_bib0025","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/ndt\/gfr357","article-title":"Remission of proteinuria and preservation of renal function in patients with renal AA amyloidosis secondary to rheumatoid arthritis","volume":"27","author":"Ueno","year":"2012","journal-title":"Nephrol Dial Transplant"},{"issue":"9275","key":"10.1016\/j.amjmed.2022.01.003_bib0026","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S0140-6736(00)05252-1","article-title":"Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein","volume":"358","author":"Gillmore","year":"2001","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.amjmed.2022.01.003_bib0027","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/ki.2013.558","article-title":"Characterization and outcomes of renal leukocyte chemotactic factor 2-associated amyloidosis","volume":"86","author":"Said","year":"2014","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.amjmed.2022.01.003_bib0028","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1681\/ASN.2008060614","article-title":"Diagnosis, pathogenesis, treatment, and prognosis of hereditary fibrinogen A alpha-chain amyloidosis","volume":"20","author":"Gillmore","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.amjmed.2022.01.003_bib0029","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/ndt\/gfs492","article-title":"End-stage renal failure due to amyloidosis: outcomes in 490 ANZDATA registry cases","volume":"28","author":"Tang","year":"2013","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"10.1016\/j.amjmed.2022.01.003_bib0030","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1200\/JCO.2010.30.5235","article-title":"Outcome in renal Al amyloidosis after chemotherapy","volume":"29","author":"Pinney","year":"2011","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.amjmed.2022.01.003_bib0031","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2215\/CJN.02470607","article-title":"Presentation and outcome of patients with systemic amyloidosis undergoing dialysis","volume":"3","author":"Boll\u00e9e","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.amjmed.2022.01.003_bib0032","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/ndt\/gfaa293","article-title":"Renal transplant outcomes in amyloidosis","volume":"36","author":"Law","year":"2021","journal-title":"Nephrol Dial Transplant"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934322000249?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934322000249?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T09:25:44Z","timestamp":1757582744000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934322000249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":32,"alternative-id":["S0002934322000249"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2022.01.003","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Renal Amyloidosis: Presentation, Diagnosis, and Management","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2022.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}